We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
-1.53%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$23.8B
AUM Growth
-$2.11B
(-8.1%)
Cap. Flow
-$941M
Cap. Flow
% of AUM
-3.95%
Top 10 Holdings %
Top 10 Hldgs %
24.95%
Holding
1,082
New
165
Increased
347
Reduced
405
Closed
129
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$293M |
| 2 |
Micron Technology
MU
|
+$214M |
| 3 |
Texas Instruments
TXN
|
+$174M |
| 4 |
Las Vegas Sands
LVS
|
+$136M |
| 5 |
SF
Stifel
SF
|
+$108M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$284M |
| 2 |
O'Reilly Automotive
ORLY
|
+$241M |
| 3 |
Arista Networks
ANET
|
+$239M |
| 4 |
Comfort Systems
FIX
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$204M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.74% |
| 2 | Financials | 13.54% |
| 3 | Consumer Discretionary | 13.12% |
| 4 | Industrials | 11.88% |
| 5 | Healthcare | 10.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Atea Pharmaceuticals
AVIR
$380M
| $232K | ﹤0.01% |
43,104
| – | – |
|
902
CVRx
CVRX
$130M
| $231K | ﹤0.01% |
+24,439
| New | +$179K |
|
|
BLD
903
DELISTED
TopBuild
BLD
| $229K | ﹤0.01% |
+653
| New | +$293K |
|
904
Bioventus
BVS
$778M
| $226K | ﹤0.01% |
24,699
-96,574
| -80% | -$810K |
|
905
Arrow Financial
AROW
$647M
| $225K | ﹤0.01% |
+6,714
| New | +$224K |
|
906
Bank7 Corp
BSVN
$480M
| $223K | ﹤0.01% |
+5,593
| New | +$236K |
|
907
PMV Pharmaceuticals
PMVP
$70.9M
| $223K | ﹤0.01% |
179,873
-344,477
| -66% | -$438K |
|
|
CAI
908
Caris Life Sciences
CAI
$4.42B
| $221K | ﹤0.01% |
+12,340
| New | +$270K |
|
909
Avnet
AVT
$7.38B
| $219K | ﹤0.01% |
+3,546
| New | +$211K |
|
910
BioLife Solutions
BLFS
$1.5B
| $212K | ﹤0.01% |
11,099
| – | – |
|
911
Trustmark
TRMK
$2.7B
| $212K | ﹤0.01% |
+5,022
| New | +$212K |
|
912
Laureate Education
LAUR
$5.12B
| $211K | ﹤0.01% |
6,045
-311,017
| -98% | -$10.7M |
|
913
Kinsale Capital Group
KNSL
$7.66B
| $209K | ﹤0.01% |
613
-12,925
| -95% | -$4.9M |
|
914
PACCAR
PCAR
$68.8B
| $208K | ﹤0.01% |
+1,800
| New | +$218K |
|
915
BayCom
BCML
$361M
| $206K | ﹤0.01% |
+6,931
| New | +$204K |
|
916
SmartFinancial
SMBK
$839M
| $206K | ﹤0.01% |
+5,267
| New | +$208K |
|
917
Biote Corp
BTMD
$68.2M
| $204K | ﹤0.01% |
151,049
+52,444
| +53% | +$105K |
|
918
Lexicon Pharmaceuticals
LXRX
$1.02B
| $203K | ﹤0.01% |
+130,020
| New | +$189K |
|
919
Vaalco Energy
EGY
$611M
| $202K | ﹤0.01% |
31,811
-1,604
| -5% | -$8.08K |
|
920
Babcock & Wilcox
BW
$1.64B
| $200K | ﹤0.01% |
+13,639
| New | +$143K |
|
921
Clean Energy Fuels
CLNE
$460M
| $186K | ﹤0.01% |
+75,115
| New | +$175K |
|
922
Nautilus Biotechnolgy
NAUT
$225M
| $180K | ﹤0.01% |
+46,394
| New | +$114K |
|
923
Replimune Group
REPL
$878M
| $177K | ﹤0.01% |
+23,199
| New | +$177K |
|
924
DocGo
DCGO
$66.2M
| $174K | ﹤0.01% |
277,300
-144,182
| -34% | -$109K |
|
925
Kaltura
KLTR
$206M
| $174K | ﹤0.01% |
142,914
-73,681
| -34% | -$105K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q1 2026 Portfolio in Review
As of Q1 2026, Jacobs Levy Equity Management held 1,082 positions worth $23.8B, down 8.1% from $25.9B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jacobs Levy Equity Management withdrew a net $941M in Q1 2026, closing 129 positions and reducing 405 holdings. Its most notable exit was Illumina, an estimated $53.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Jacobs Levy Equity Management opened a new position in Texas Instruments worth $166M.
- Jacobs Levy Equity Management's largest Q1 2026 buy was Texas Instruments: 857,024 shares worth $166M.
- Jacobs Levy Equity Management added most to Alphabet (Google) Class C in Q1 2026, an estimated $293M increase.
- Jacobs Levy Equity Management's biggest Q1 2026 reduction was Lam Research, cutting an estimated $284M.
- Jacobs Levy Equity Management fully exited Illumina in Q1 2026, selling an estimated $53.1M.
- Jacobs Levy Equity Management's ten largest holdings make up 25% of its $23.8B portfolio in Q1 2026.
- Jacobs Levy Equity Management opened 165 new positions and closed 129 in Q1 2026.
- Jacobs Levy Equity Management's portfolio value fell 8.1% quarter-over-quarter to $23.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.